US health plans | Make the medicines case explicit

A pharmacy director, medical-policy lead or finance sponsor might be deciding whether a service proposition deserves a formal evaluation. The first task is to state the decision authority and the organisation’s benefit setting. Commercial insurance, Medicare and Medicaid should not be collapsed into one market. The incentive is a clearer review, fewer unresolved assumptions and a more defensible allocation of evaluation resources, not automatic approval of a preferred product.

We propose taking one completed or pending non-patient-specific business question and preparing a structured evidence brief. Inputs could include the plan’s approved question, public literature, policy documents and authorised aggregate utilisation summaries. The comparison would be the current committee preparation process. Both methods would have to answer the same questions about relevance, uncertainty, implementation demands and the information missing before a decision can be made.

The review would separate plan expenditure, member affordability, provider work and supplier revenue. A lower figure in one column does not guarantee a better overall result. If confidential rebates or guarantees are unavailable, the output should show that limitation rather than invent a net price. Any modelled scenario would state its assumptions and sensitivity. A clinical claim would require appropriate evidence and professional review, not an attractive financial chart.

HHS de-identification guidance is relevant if the plan proposes using health information (HHS, n.d.). An initial study should avoid individual records where an aggregate question is sufficient. The plan would confirm permitted uses, access and disclosure controls before any data transfer. A subsequent analysis requiring person-level linkage would be a different undertaking, with its own governance, methodology and justification. It should not quietly become part of an introductory commercial demonstration.

We would stop if the question lacks an accountable decision owner, the necessary evidence cannot be used or the review introduces material errors that the normal process would avoid. Continuation would require a repeated preparation problem and a credible willingness to pay for its solution. The first agreement should specify a deliverable and review standard. It should not bundle a promise of reduced claims expenditure with an untested evidence workflow.

Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.